Structure Therapeutics Inc. Increase (Decrease) in Other Noncurrent Assets
Structure Therapeutics Inc. (GPCR) reported Increase (Decrease) in Other Noncurrent Assets of $40.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-06
- Structure Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was $35.44M, a 33333.96% increase year-over-year.
- Structure Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was $4.84M, a 388.69% increase year-over-year.
- Structure Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was -$5.88M, a 279.11% decline year-over-year.
- Structure Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $397.00K.
- Structure Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2025 was -$4.39M, a 186.72% decline from fiscal 2024.
- Structure Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2024 was $5.06M.
- Structure Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2023 was -$15.00K, a 125.00% decline from fiscal 2022.
- Structure Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2022 was $60.00K.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $40.28M 10-Q · filed 2026-08-06 | $34.40M derived: sum of 3 quarters · filed 2026-08-06 | $34.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.84M 10-Q · filed 2026-05-07 | -$1.04M derived: sum of 2 quarters · filed 2026-05-07 | -$647.00K derived: sum of 3 quarters · filed 2026-05-07 | -$541.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$5.49M derived: sum of 2 quarters · filed 2026-02-26 | -$5.38M derived: sum of 3 quarters · filed 2026-08-06 | -$4.39M 10-K · filed 2026-02-26 |
| 2025-09-30 | $397.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $503.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.49M 10-Q · filed 2025-11-06 | $4.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.10M 10-Q · filed 2026-08-06 | $4.38M derived: sum of 3 quarters · filed 2026-08-06 | $4.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $990.00K 10-Q · filed 2026-05-07 | $4.27M derived: sum of 2 quarters · filed 2026-05-07 | $4.27M derived: sum of 3 quarters · filed 2026-05-07 | $6.05M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.28M derived: sum of 2 quarters · filed 2026-02-26 | $5.06M derived: sum of 3 quarters · filed 2026-02-26 | $5.06M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.77M derived: sum of 2 quarters · filed 2025-11-06 | $1.78M 10-Q · filed 2025-11-06 | $1.78M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.78M 10-Q · filed 2025-08-06 | $1.79M derived: sum of 3 quarters · filed 2026-02-26 | $1.79M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.00K 10-Q · filed 2025-05-08 | $9.00K derived: sum of 2 quarters · filed 2026-02-26 | $9.00K derived: sum of 3 quarters · filed 2026-02-26 | -$72.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.00K derived: sum of 2 quarters · filed 2026-02-26 | -$74.00K derived: sum of 3 quarters · filed 2026-02-26 | -$15.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$81.00K derived: sum of 2 quarters · filed 2024-11-13 | -$22.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$22.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $59.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $60.00K 10-K · filed 2024-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |